To Get Full Access :

Rezdiffra

Rezdiffra is a prescription medication indicated for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) in individuals with mild to severe hepatic fibrosis. It is used to promote improved liver health in conjunction with a balanced diet and consistent exercise.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Resmetirom
  • Innovator :

    MADRIGAL PHARMACEUTICALS INC
  • Approval Date :

    14-Mar-24
  • NCE-1 Date :

    14-Mar-28
  • NCE Date :

    14-Mar-29
  • Dosage Form :

    Tablet
  • Strength :

    60mg, 80mg, 100mg
  • Therapeutic Category :

    Antimetabolic Disorder
  • Revenue ($M) :

    958

Year-wise Projected Sales ($M) :

  • 2026 :

    1472
  • 2027 :

    2173
  • 2028 :

    2940
  • 2029 :

    3852
  • 2030 :

    4807
  • 2031 :

    5750
  • 2032 :

    6553
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?